HCPCS Level II
Q5126
Injection, bevacizumab-maly, biosimilar, (alymsys), 10 mg
Codes near Q5126
These sit next to Q5126 in the CMS Level II file. All Q codes
- Q5121Injection, infliximab-axxq, biosimilar, (avsola), 10 mg
- Q5122Injection, pegfilgrastim-apgf (nyvepria), biosimilar, 0.5 mg
- Q5123Injection, rituximab-arrx, biosimilar, (riabni), 10 mg
- Q5124Injection, ranibizumab-nuna, biosimilar, (byooviz), 0.1 mg
- Q5125Injection, filgrastim-ayow, biosimilar, (releuko), 1 microgram
- Q5127Injection, pegfilgrastim-fpgk (stimufend), biosimilar, 0.5 mg
- Q5128Injection, ranibizumab-eqrn (cimerli), biosimilar, 0.1 mg
- Q5129Injection, bevacizumab-adcd (vegzelma), biosimilar, 10 mg
- Q5130Injection, pegfilgrastim-pbbk (fylnetra), biosimilar, 0.5 mg
- Q5131Injection, adalimumab-aacf (idacio), biosimilar, 20 mg
NDC crosswalk
| NDC | Drug | Labeler | Billable units |
|---|---|---|---|
| 70121-1754-01 | Alymsys | Amneal Pharmaceuticals, LLC | 10 |
| 70121-1755-01 | Alymsys | Amneal Pharmaceuticals, LLC | 40 |
| 85006-1754-01 | Alymsys | Valorum Biologics, LLC | 10 |
| 85006-1755-01 | Alymsys | Valorum Biologics, LLC | 40 |
Source: CMS ASP NDC-HCPCS crosswalk, effective October 1, 2026 through December 31, 2026.